Physician profile
Thomas Christopher Smith
NPI 1013303262
$2,768.90
in general payments reported to CMS, 2019-2025
30 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $161 · 2021: $281 · 2022: $212 · 2023: $53.31 · 2024: $348 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,622.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $449.44 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $286.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $269.59 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $212.67 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Abbvie INC. | $171.70 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.32 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $141.52 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $135.89 | 2019-2025 | Zepbound, Mounjaro |
| Amgen INC. | $131.63 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $116.55 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $102.31 | 2021-2025 | Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $54.40 | 2021-2022 | |
| Axsome Therapeutics, INC. | $51.22 | 2025 | Sunosi, Auvelity |
| Xeris Pharmaceuticals, INC. | $50.43 | 2022 | |
| Exact Sciences Corporation | $46.47 | 2024-2025 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.69 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.02 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $34.31 | 2025 | Gemtesa |
| Dexcom, INC. | $33.21 | 2021-2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $32.58 | 2022 | |
| Amarin Pharma, INC. | $31.93 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $29.56 | 2025 | Voquezna |
| Lundbeck LLC | $22.12 | 2025 | Rexulti |
| Corcept Therapeutics | $21.36 | 2025 | Korlym |
| Tolmar, INC. | $21.26 | 2025 | |
| Vanda Pharmaceuticals INC. | $19.29 | 2025 | Fanapt |
| Abiomed | $18.45 | 2025 | |
| Avanir Pharmaceuticals, INC. | $18.29 | 2019 | |
| Biogen, INC. | $16.03 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.62 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.